Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.

  • 1.

    Al-HamadaniMHabermannTMCerhanJR. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol2015;90:790795.

    • Search Google Scholar
    • Export Citation
  • 2.

    AlizadehAAEisenMBDavisRE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature2000;403:503511.

    • Search Google Scholar
    • Export Citation
  • 3.

    HansCPWeisenburgerDDGreinerTC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood2004;103:275282.

    • Search Google Scholar
    • Export Citation
  • 4.

    ChoiWWLWeisenburgerDDGreinerTC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res2009;15:54945502.

    • Search Google Scholar
    • Export Citation
  • 5.

    MeyerPNFuKGreinerTC. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol2011;29:200207.

    • Search Google Scholar
    • Export Citation
  • 6.

    SavageKJJohnsonNABen-NeriahS. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood2009;114:35333537.

    • Search Google Scholar
    • Export Citation
  • 7.

    BarransSCrouchSSmithA. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol2010;28:33603365.

    • Search Google Scholar
    • Export Citation
  • 8.

    TzankovAXu-MonetteZYGerhardM. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol2014;27:958971.

    • Search Google Scholar
    • Export Citation
  • 9.

    NowakowskiGSLaPlantBMaconWR. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol2015;33:251257.

    • Search Google Scholar
    • Export Citation
  • 10.

    WilsonWHYoungRMSchmitzR. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med2015;21:922926.

    • Search Google Scholar
    • Export Citation
  • 11.

    MozosARoyoCHartmannE. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica2009;94:15551562.

    • Search Google Scholar
    • Export Citation
  • 12.

    ZengWFuKQuintanilla-FendL. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol2012;36:214219.

    • Search Google Scholar
    • Export Citation
  • 13.

    FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab); September252013. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM369436.pdf.

    • Search Google Scholar
    • Export Citation
  • 14.

    JuweidME. FDG-PET/CT in lymphoma. Methods Mol Biol2011;727:119.

  • 15.

    ChesonBDFisherRIBarringtonSF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol2014;32:30593068.

    • Search Google Scholar
    • Export Citation
  • 16.

    AdamsHJKweeTCde KeizerB. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging2014;41:565574.

    • Search Google Scholar
    • Export Citation
  • 17.

    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med1993;329:987994.

    • Search Google Scholar
    • Export Citation
  • 18.

    SehnLHBerryBChhanabhaiM. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard ipi for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood2006;109:18571861.

    • Search Google Scholar
    • Export Citation
  • 19.

    ZhouZSehnLHRademakerAW. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood2014;123:837842.

    • Search Google Scholar
    • Export Citation
  • 20.

    El-GalalyTCVillaDAlzahraniM. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol2015;90:10411046.

    • Search Google Scholar
    • Export Citation
  • 21.

    ZuccaEConconiAMughalTI. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol2003;21:2027.

    • Search Google Scholar
    • Export Citation
  • 22.

    LaskinJJSavageKJVossN. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma2005;46:17211727.

    • Search Google Scholar
    • Export Citation
  • 23.

    ShimazuYNotoharaKUedaY. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol2009;89:577583.

    • Search Google Scholar
    • Export Citation
  • 24.

    SchmitzNZeynalovaSNickelsenM. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematological Oncology2013;31(Suppl 1):Abstract 047.

    • Search Google Scholar
    • Export Citation
  • 25.

    SavageKJZeynalovaSKansaraRR. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma [abstract]. Blood2014;124:Abstract 394.

    • Search Google Scholar
    • Export Citation
  • 26.

    MillerTPDahlbergSCassadyJR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med1998;339:2126.

    • Search Google Scholar
    • Export Citation
  • 27.

    ShenkierTNVossNFaireyR. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol2002;20:197204.

    • Search Google Scholar
    • Export Citation
  • 28.

    HorningSJWellerEKimK. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol2004;22:30323038.

    • Search Google Scholar
    • Export Citation
  • 29.

    BonnetCFilletGMounierN. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol2007;25:787792.

    • Search Google Scholar
    • Export Citation
  • 30.

    PerskyDOUngerJMSpierCM. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol2008;26:22582263.

    • Search Google Scholar
    • Export Citation
  • 31.

    PfreundschuhMTrumperLOsterborgA. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol2006;7:379391.

    • Search Google Scholar
    • Export Citation
  • 32.

    PfreundschuhMKuhntETrumperL. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol2011;12:10131022.

    • Search Google Scholar
    • Export Citation
  • 33.

    OdejideOOCroninAMDavidoffAJ. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma2015;56:716724.

    • Search Google Scholar
    • Export Citation
  • 34.

    FisherRIGaynorERDahlbergS. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med1993;328:10021006.

    • Search Google Scholar
    • Export Citation
  • 35.

    CoiffierBLepageEBriereJ. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med2002;346:235242.

    • Search Google Scholar
    • Export Citation
  • 36.

    FeugierPVan HoofASebbanC. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol2005;23:41174126.

    • Search Google Scholar
    • Export Citation
  • 37.

    CoiffierBThieblemontCVan Den NesteE. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood2010;116:20402045.

    • Search Google Scholar
    • Export Citation
  • 38.

    SonneveldPvan PuttenWHolteH. Intensified CHOP with rituximab for intermediate or high-risk Non-hodgkin's lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups [abstract]. Blood2005;106:Abstract 16.

    • Search Google Scholar
    • Export Citation
  • 39.

    HabermannTMWellerEAMorrisonVA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol2006;24:31213127.

    • Search Google Scholar
    • Export Citation
  • 40.

    BlayneyDWLeBlancMLGroganT. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol2003;21:24662473.

    • Search Google Scholar
    • Export Citation
  • 41.

    HalaasJLMoskowitzCHHorwitzS. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma2005;46:541547.

    • Search Google Scholar
    • Export Citation
  • 42.

    PfreundschuhMTrumperLKloessM. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 43.

    PfreundschuhMSchubertJZiepertM. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol2008;9:105116.

    • Search Google Scholar
    • Export Citation
  • 44.

    PfreundschuhMZiepertMZeynalovaS. Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL [abstract]. J Clin Oncol2011;29:Abstract 8029.

    • Search Google Scholar
    • Export Citation
  • 45.

    HeldGMurawskiNZiepertM. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol2014;32:11121118.

    • Search Google Scholar
    • Export Citation
  • 46.

    HeldGZeynalovaSMurawskiN. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol2013;31:41154122.

    • Search Google Scholar
    • Export Citation
  • 47.

    CunninghamDHawkesEAJackA. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet2013;381:18171826.

    • Search Google Scholar
    • Export Citation
  • 48.

    DelarueRTillyHMounierN. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol2013;14:525533.

    • Search Google Scholar
    • Export Citation
  • 49.

    SchmitzNNickelsenMZiepertM. Optimization of rituximab for treatment of DLBCL in young, high-risk patients-results of the dense-R-CHOEP Trial of the German high-grade lymphoma study group. Blood2015;126:474474.

    • Search Google Scholar
    • Export Citation
  • 50.

    PfreundschuhMMullerCZeynalovaS. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood2014;123:640646.

  • 51.

    PfreundschuhMHeldGZeynalovaS. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results from the SEXIE-R-CHOP-14 trial of the DSHNHL [abstract]. J Clin Oncol2014;32 (15_suppl):Abstract 8501.

    • Search Google Scholar
    • Export Citation
  • 52.

    WilsonWHJungSHPorcuP. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica2012;97:758765.

    • Search Google Scholar
    • Export Citation
  • 53.

    PurroyNBerguaJGallurL. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol2015;169:188198.

    • Search Google Scholar
    • Export Citation
  • 54.

    PeyradeFJardinFThieblemontC. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol2011;12:460468.

    • Search Google Scholar
    • Export Citation
  • 55.

    PeyradeFFainOFabianiB. Long-term follow-up of the GELA LNH 03-7B study: a prospective phase II study of 150 patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with RminiCHOP [abstract]. J Clin Oncol2013;31(15_suppl):Abstract 8536.

    • Search Google Scholar
    • Export Citation
  • 56.

    HaiounCLepageEGisselbrechtC. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol: a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol2000;18:30253030.

    • Search Google Scholar
    • Export Citation
  • 57.

    StiffPJUngerJMCookJR. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med2013;369:16811690.

    • Search Google Scholar
    • Export Citation
  • 58.

    Le GouillSMilpiedNJLamyT. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicenter randomized trial [abstract]. J Clin Oncol2011;29:Abstract 8003.

    • Search Google Scholar
    • Export Citation
  • 59.

    SchmitzNNickelsenMZiepertM. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol2012;13:12501259.

    • Search Google Scholar
    • Export Citation
  • 60.

    VitoloUChiappellaABrusamolinoE. Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL) [absttract]. Blood2012;120:Abstract 688.

    • Search Google Scholar
    • Export Citation
  • 61.

    AbramsonJSHellmannMBarnesJA. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer2010;116:42834290.

    • Search Google Scholar
    • Export Citation
  • 62.

    HolteHLeppaSBjorkholmM. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol2013;24:13851392.

    • Search Google Scholar
    • Export Citation
  • 63.

    CheahCYHerbertKEO'RourkeK. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer2014;111:10721079.

    • Search Google Scholar
    • Export Citation
  • 64.

    FerreriAJBruno-VentreMDonadoniG. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol2015;168:654662.

    • Search Google Scholar
    • Export Citation
  • 65.

    KumarAVanderplasALaCasceAS. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer2012;118:29442951.

    • Search Google Scholar
    • Export Citation
  • 66.

    TomitaNTakasakiHIshiyamaY. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma2015;56:725729.

    • Search Google Scholar
    • Export Citation
  • 67.

    MikhaeelNGTimothyARO'DohertyMJ. 18-FDG-PET as a prognostic1. indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma2000;39:543553.

    • Search Google Scholar
    • Export Citation
  • 68.

    SpaepenKStroobantsSDupontP. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol2002;13:13561363.

    • Search Google Scholar
    • Export Citation
  • 69.

    HaiounCIttiERahmouniA. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood2005;106:13761381.

    • Search Google Scholar
    • Export Citation
  • 70.

    DupuisJIttiERahmouniA. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol2009;20:503507.

    • Search Google Scholar
    • Export Citation
  • 71.

    MoskowitzCHSchoderHTeruya-FeldsteinJ. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol2010;28:18961903.

    • Search Google Scholar
    • Export Citation
  • 72.

    PregnoPChiappellaABelloM. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood2012;119:20662073.

    • Search Google Scholar
    • Export Citation
  • 73.

    CarrRFantiSPaezD. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med2014;55:19361944.

    • Search Google Scholar
    • Export Citation
  • 74.

    DabajaBSVanderplasAMCrosby-ThompsonAL. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer2015;121:10321039.

    • Search Google Scholar
    • Export Citation
  • 75.

    MamotCKlingbielDHitzF. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol2015;33:25232529.

    • Search Google Scholar
    • Export Citation
  • 76.

    SwinnenLJLiHQuonA. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol2015;170:5665.

    • Search Google Scholar
    • Export Citation
  • 77.

    BarringtonSFMikhaeelNGKostakogluL. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol2014;32:30483058.

    • Search Google Scholar
    • Export Citation
  • 78.

    BarringtonSFQianWSomerEJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging2010;37:18241833.

    • Search Google Scholar
    • Export Citation
  • 79.

    MeignanMGallaminiAHaiounCPolliackA. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma2010;51:21712180.

    • Search Google Scholar
    • Export Citation
  • 80.

    MeignanMGallaminiAIttiE. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma2012;53:18761881.

    • Search Google Scholar
    • Export Citation
  • 81.

    GuppyAETebbuttNCNormanACunninghamD. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma2003;44:123125.

    • Search Google Scholar
    • Export Citation
  • 82.

    LiedtkeMHamlinPAMoskowitzCHZelenetzAD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol2006;17:909913.

    • Search Google Scholar
    • Export Citation
  • 83.

    ZinzaniPLStefoniVTaniM. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol2009;27:17811787.

    • Search Google Scholar
    • Export Citation
  • 84.

    PetrauschUSamarasPHaileSR. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol2010;21:16941698.

    • Search Google Scholar
    • Export Citation
  • 85.

    AviviIZilberlichtADannEJ. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol2013;88:400405.

    • Search Google Scholar
    • Export Citation
  • 86.

    CheahCYHofmanMSDickinsonM. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer2013;109:312317.

    • Search Google Scholar
    • Export Citation
  • 87.

    ThompsonCAGhesquieresHMaurerMJ. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol2014;32:35063512.

    • Search Google Scholar
    • Export Citation
  • 88.

    El-GalalyTCJakobsenLHHutchingsM. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study. J Clin Oncol2015;33:39933998.

    • Search Google Scholar
    • Export Citation
  • 89.

    MaurerMJGhesquieresHJaisJP. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol2014;32:10661073.

    • Search Google Scholar
    • Export Citation
  • 90.

    PhilipTGuglielmiCHagenbeekA. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med1995;333:15401545.

    • Search Google Scholar
    • Export Citation
  • 91.

    MounierNCanalsCGisselbrechtC. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant2012;18:788793.

    • Search Google Scholar
    • Export Citation
  • 92.

    HamlinPAZelenetzADKewalramaniT. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood2003;102:19891996.

    • Search Google Scholar
    • Export Citation
  • 93.

    LernerREThomasWDeforTE. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant2007;13:486492.

    • Search Google Scholar
    • Export Citation
  • 94.

    DerenziniEMusuracaGFantiS. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer2008;113:24962503.

    • Search Google Scholar
    • Export Citation
  • 95.

    SpaepenKStroobantsSDupontP. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood2003;102:5359.

    • Search Google Scholar
    • Export Citation
  • 96.

    TrnenyMBoslyABouabdallahK. Independent predictive value of PET-CT pre transplant in relapsed and refractory patients with CD20 diffuse large B-cell lymphoma (DLBCL) included in the CORAL study [abstract]. Blood2009;114:Abstract 881.

    • Search Google Scholar
    • Export Citation
  • 97.

    HoppeBSMoskowitzCHZhangZ. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant2009;43:941948.

    • Search Google Scholar
    • Export Citation
  • 98.

    VoseJMZhangMJRowlingsPA. Autologous transplantation for diffuse aggressive Non-hodgkin's lymphoma in patients never achieving remission: a report from the autologous Blood and Marrow Transplant Registry. J Clin Oncol2001;19:406413.

    • Search Google Scholar
    • Export Citation
  • 99.

    CaballeroMDPérez-SimónJAIriondoA. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Annals of Oncology2003;14:140151.

    • Search Google Scholar
    • Export Citation
  • 100.

    RodriguezJCaballeroMDGutierrezA. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Annals of Oncology2004;15:15041509.

    • Search Google Scholar
    • Export Citation
  • 101.

    CoiffierBHaiounCKettererN. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood1998;92:19271932.

    • Search Google Scholar
    • Export Citation
  • 102.

    MeyUJOrloppKSFliegerD. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest2006;24:593600.

    • Search Google Scholar
    • Export Citation
  • 103.

    VelasquezWSMcLaughlinPTuckerS. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol1994;12:11691176.

    • Search Google Scholar
    • Export Citation
  • 104.

    JoyceRMReganMOttawayJ. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol2003;14Suppl 1:2127.

    • Search Google Scholar
    • Export Citation
  • 105.

    ZelenetzADHamlinPKewalramaniT. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol2003;14Suppl 1:i510.

    • Search Google Scholar
    • Export Citation
  • 106.

    VoseJSnellerV. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol2003;14Suppl 1:1720.

    • Search Google Scholar
    • Export Citation
  • 107.

    KewalramaniTZelenetzADNimerSD. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood2004;103:36843688.

    • Search Google Scholar
    • Export Citation
  • 108.

    GutierrezMChabnerBAPearsonD. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol2000;18:36333642.

    • Search Google Scholar
    • Export Citation
  • 109.

    JermannMJostLMTavernaC. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol2004;15:511516.

    • Search Google Scholar
    • Export Citation
  • 110.

    ChaoNJRosenbergSAHorningSJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood1990;76:12931298.

    • Search Google Scholar
    • Export Citation
  • 111.

    GisselbrechtCGlassBMounierN. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraJ Clin Oncol2010;28:41844190.

    • Search Google Scholar
    • Export Citation
  • 112.

    GisselbrechtCSchmitzNMounierN. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol2012;30:44624469.

    • Search Google Scholar
    • Export Citation
  • 113.

    CuccuiniWBriereJMounierN. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood2012;119:46194624.

    • Search Google Scholar
    • Export Citation
  • 114.

    ThieblemontCBriereJMounierN. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol2011;29:40794087.

    • Search Google Scholar
    • Export Citation
  • 115.

    CrumpMBaetzTCoubanS. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer2004;101:18351842.

    • Search Google Scholar
    • Export Citation
  • 116.

    El GnaouiTDupuisJBelhadjK. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol2007;18:13631368.

    • Search Google Scholar
    • Export Citation
  • 117.

    LopezAGutierrezAPalaciosA. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol2008;80:127132.

    • Search Google Scholar
    • Export Citation
  • 118.

    CorazzelliGCapobiancoGArcamoneM. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol2009;64:907916.

    • Search Google Scholar
    • Export Citation
  • 119.

    MounierNEl GnaouiTTillyH. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica2013;98:17261731.

    • Search Google Scholar
    • Export Citation
  • 120.

    CrumpMKuruvillaJCoubanS. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol2014;32:34903496.

    • Search Google Scholar
    • Export Citation
  • 121.

    WeidmannEKimSZRostA. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol2002;13:12851289.

    • Search Google Scholar
    • Export Citation
  • 122.

    OguraMAndoKTaniwakiM. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma(6). Cancer Sci2011;102:16871692.

    • Search Google Scholar
    • Export Citation
  • 123.

    OhmachiKNiitsuNUchidaT. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol2013;31:21032109.

    • Search Google Scholar
    • Export Citation
  • 124.

    VacircaJLAcsPITabbaraIA. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol2014;93:403409.

    • Search Google Scholar
    • Export Citation
  • 125.

    WiernikPHLossosISTuscanoJM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol2008;26:49524957.

    • Search Google Scholar
    • Export Citation
  • 126.

    WitzigTEVoseJMZinzaniPL. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol2011;22:16221627.

    • Search Google Scholar
    • Export Citation
  • 127.

    Hernandez-IlizaliturriFJDeebGZinzaniPL. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer2011;117:50585066.

    • Search Google Scholar
    • Export Citation
  • 128.

    WangMFowlerNWagner-BartakN. Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia2013;27:19021909.

    • Search Google Scholar
    • Export Citation
  • 129.

    ZinzaniPLVoseJMCzuczmanMS. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol2013;24:28922897.

    • Search Google Scholar
    • Export Citation
  • 130.

    CzuczmanMSDaviesALintonKM. A Phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL. Blood2014;124:628628.

    • Search Google Scholar
    • Export Citation
  • 131.

    JacobsenEDSharmanJPOkiY. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood2015;125:13941402.

    • Search Google Scholar
    • Export Citation
  • 132.

    HoppeBSMoskowitzCHFilippaDA. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol2008;26:18581864.

    • Search Google Scholar
    • Export Citation
  • 133.

    Cazals-HatemDLepageEBriceP. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol1996;20:877888.

    • Search Google Scholar
    • Export Citation
  • 134.

    FarisJELaCasceAS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol2009;7:125133.

  • 135.

    RosenwaldAWrightGLeroyK. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med2003;198:851862.

    • Search Google Scholar
    • Export Citation
  • 136.

    SavageKJMontiSKutokJL. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood2003;102:38713879.

    • Search Google Scholar
    • Export Citation
  • 137.

    HamlinPAPortlockCSStrausDJ. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol2005;130:691699.

    • Search Google Scholar
    • Export Citation
  • 138.

    SavageKJAl-RajhiNVossN. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol2006;17:123130.

    • Search Google Scholar
    • Export Citation
  • 139.

    TodeschiniGSecchiSMorraE. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer2004;90:372376.

    • Search Google Scholar
    • Export Citation
  • 140.

    ZinzaniPLMartelliMBertiniM. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica2002;87:12581264.

    • Search Google Scholar
    • Export Citation
  • 141.

    De SanctisVFinolezziEOstiMF. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys2008;72:11541160.

    • Search Google Scholar
    • Export Citation
  • 142.

    MazzarottoRBosoCVianelloF. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients: a single institution experience. Int J Radiat Oncol Biol Phys2007;68:823829.

    • Search Google Scholar
    • Export Citation
  • 143.

    ZinzaniPLStefoniVFinolezziE. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma2009;9:381385.

    • Search Google Scholar
    • Export Citation
  • 144.

    RiegerMOsterborgAPettengellR. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol2011;22:664670.

    • Search Google Scholar
    • Export Citation
  • 145.

    VassilakopoulosTPPangalisGAKatsigiannisA. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist2012;17:239249.

    • Search Google Scholar
    • Export Citation
  • 146.

    Witzens-HarigMHoADKuhntE. Primary mediastinal B cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: 5-year results of the Mabthera International Trial Group (MInT) study [abstract]. Blood2012;120:Abstract 1612.

    • Search Google Scholar
    • Export Citation
  • 147.

    AvigdorASirotkinTKedmiM. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol2014;93:12971304.

    • Search Google Scholar
    • Export Citation
  • 148.

    MoskowitzCHamlinPAJr.MaraguliaJ. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma[abstract]. Blood2010;116:Abstract 420.

    • Search Google Scholar
    • Export Citation
  • 149.

    SoumeraiJDHellmannMDFengY. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma2014;55:538543.

    • Search Google Scholar
    • Export Citation
  • 150.

    DunleavyKPittalugaSMaedaLS. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med2013;368:14081416.

    • Search Google Scholar
    • Export Citation
  • 151.

    BinkleyMSHinikerSMWuS. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma2015:15.

    • Search Google Scholar
    • Export Citation
  • 152.

    MartelliMCerianiLZuccaE. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol2014;32:17691775.

    • Search Google Scholar
    • Export Citation
  • 153.

    PinnixCCDabajaBAhmedMA. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys2015;92:113121.

    • Search Google Scholar
    • Export Citation
  • 154.

    JaffeESSteinHSwerdlowSH. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: SwerdlowSHCampoEHarrisNL. eds. WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4th). Lyon: IARC; 2008:267268.

    • Search Google Scholar
    • Export Citation
  • 155.

    Quintanilla-MartinezLde JongDde MascarelA. Gray zones around diffuse large B cell lymphoma: conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop2009;2:211236.

    • Search Google Scholar
    • Export Citation
  • 156.

    HoellerSCopie-BergmanC. Grey zone lymphomas: lymphomas with intermediate features. Adv Hematol2012;2012:460801.

  • 157.

    GualcoGNatkunamYBacchiCE. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol2012;25:661674.

    • Search Google Scholar
    • Export Citation
  • 158.

    EvensAMKanakryJASehnLH. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol2015;90:778783.

    • Search Google Scholar
    • Export Citation
  • 159.

    Traverse-GlehenAPittalugaSGaulardP. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol2005;29:14111421.

    • Search Google Scholar
    • Export Citation
  • 160.

    EberleFCRodriguez-CanalesJWeiL. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica2011;96:558566.

    • Search Google Scholar
    • Export Citation
  • 161.

    GarciaJFMollejoMFragaM. Large B-cell lymphoma with Hodgkin's features. Histopathology2005;47:101110.

  • 162.

    WilsonWHPittalugaSNicolaeA. A prospective study of mediastinal gray-zone lymphoma. Blood2014;124:15631569.

  • 163.

    GreenTMYoungKHViscoC. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol2012;30:34603467.

    • Search Google Scholar
    • Export Citation
  • 164.

    JohnsonNASlackGWSavageKJ. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol2012;30:34523459.

    • Search Google Scholar
    • Export Citation
  • 165.

    SnuderlMKolmanOKChenYB. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol2010;34:327340.

    • Search Google Scholar
    • Export Citation
  • 166.

    Le GouillSTalmantPTouzeauC. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica2007;92:13351342.

    • Search Google Scholar
    • Export Citation
  • 167.

    AukemaSMSiebertRSchuuringE. Double-hit B-cell lymphomas. Blood2011;117:23192331.

  • 168.

    PetrichAMGandhiMJovanovicB. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood2014;124:23542361.

    • Search Google Scholar
    • Export Citation
  • 169.

    OkiYNooraniMLinP. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol2014;166:891901.

  • 170.

    SunHSavageKJKarsanA. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk2015;15:341348.

    • Search Google Scholar
    • Export Citation
  • 171.

    HowlettCSnedecorSJLandsburgDJ. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol2015;170:504514.

    • Search Google Scholar
    • Export Citation
  • 172.

    DunleavyKFanaleMLaCasceA. Preliminary report of a multicenter prospective phase ii study of DA-EPOCH-R in MYC-rearranged aggressive b-cell lymphoma [abstract]. Blood2014;124:Abstract

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 496 496 46
PDF Downloads 194 194 24
EPUB Downloads 0 0 0